Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock increase of over 6% following the announcement of its registration application for a new treatment for myopia in children, which has been accepted for review by the Australian Therapeutic Goods Administration [1] Group 1: Company Announcement - On January 13, Zhaoke Ophthalmology-B announced that its registration application for the atropine sulfate eye drops (0.01% dosage, product code: NVK002) aimed at treating progressive myopia in children has been accepted for evaluation by the Australian Therapeutic Goods Administration [1] - The Therapeutic Goods Administration has officially informed the company that the application has passed the preliminary review and will undergo further evaluation [1] - The application is based on supportive results from the company's Phase III clinical trials [1] Group 2: Product Details - Atropine sulfate eye drops (NVK002) are a novel experimental topical ophthalmic solution designed to control the progression of myopia in children and adolescents [1] - The formulation of atropine sulfate eye drops (NVK002) is patented and successfully addresses the instability of low-concentration atropine, with intellectual property protection globally [1] - The product is preservative-free and is expected to have a shelf life of over 24 months [1]
兆科眼科-B午后涨超6% 澳洲治疗用品管理局受理评核硫酸阿托品滴眼液注册申请